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ABSTRACT: Extracellular vesicles are emerging as biomarkers
in breast cancer. Our recent report suggested that an intra-
cellular granular staining pattern of the extracellular matrix
protein nephronectin (NPNT) in breast tumor sections corre-
lated with a poor prognosis. Furthermore, the results showed
that NPNT is localized in extracellular vesicles derived from
mouse breast cancer cells. In this study, we performed proteo-
mic analysis that revealed that several proteins, including
tumor-promoting molecules, are differentially expressed in the
cargo of small extracellular vesicles (sEVs) derived from NPNT-
expressing mouse breast cancer cells. We also identified three
different forms of NPNT at 80, 60, and 20 kDa. We report that
the native form of NPNT at 60 kDa becomes further glyco-
sylated and is detected as the 80 kDa NPNT, which may be processed by matrix metalloproteinases to a shorter form of around
20 kDa, which has not previously been described. Although both 80 and 20 kDa NPNT are detected in sEVs derived from
breast cancer cells, the 20 kDa form of NPNT is concentrated in sEVs. In summary, we show that a novel truncated form of
NPNT is found in sEVs derived from breast cancer cells.
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1. INTRODUCTION
Extracellular vesicles can be classified according to their size: exo-
somes (30−100 nm), microvesicles (100−1000 nm), apopto-
tic bodies (50 nm to 2 μm), and oncosomes (1−10 μm).1
Microvesicles are bilipid-membrane vesicles originating from the
plasma membrane,2 initially disregarded as cellular debris but
now recognized as biologically significant.3,4 Extracellular
proteins may enter into the intraluminal vesicles (ILVs) within
multivesicular bodies (MVBs)2 on inward budding of the plasma
membrane. The invaginations of the limiting membrane of the
MVBs further allow several intracellular proteins to enter into
the ILVs.5,6 The content of MVBs is either released as exosomes
into the extracellular milieu or into the lysosomes for degrada-
tion.7,8 The secreted exosomes may release their contents into a
recipient cell by fusion or interact with the target cells via cell
surface proteins.9,10 Ultracentrifugation is regarded as the
gold standard for exosome isolation.11,12 However, it has been
found that the pellet of vesicles obtained after spinning
the supernatant of cells at 100 000g for 70 min contains a
heterogeneous population of membrane vesicles, in addition
to enriched exosomes.13−16 Therefore, the preferred terminol-
ogy for the isolated fraction is small extracellular vesicles
(sEVs).17
The content of sEVs is not random;18 rather, the cargo is cell
and disease-type specific and may deliver discrete molecular
messages that inflict a biological response.19 sEVs are found to
carry proteins,20 lipids,21 transposable genetic elements,22
double-stranded DNA,23 mitochondrial DNA,24 and several
types of RNAs.25 Several extracellular matrix (ECM) proteins,
such as collagens,26 fibronectin,27 vitronectin,28 and nephro-
nectin (NPNT), are found in sEVs.29 NPNT has previously
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been reported in isolated sEVs from human ductal
saliva,30 colorectal cancer cells,31 and mouse breast cancer
cells.32,33
Breast cancer is a heterogeneous disease and intercellular vesi-
cular communication via sEVs may add to the complexity of the
disease.34 The sEVs released by breast cancer cells can survive in
acidic and hypoxic environments and deliver procancerous
proteins and transcripts to their target cells.35 This induces a
range of cellular responses within their target cells, to promote
breast cancer development, progression, metastasis, and resis-
tance toward therapy.33,36−38 We have previously reported a
correlation between intracellular granular NPNT staining
pattern and decreased survival of breast cancer patients.32 This
granular staining pattern could represent NPNT-containing
MVBs in tumor cells. Similar NPNT-positive granules have been
observed in MMTV-PyMT tumor tissues and lung metastases
from NPNT-expressing 66cl4 mouse breast cancer cells.32
Furthermore, we have shown that NPNT is localized in sEVs
isolated from 66cl4 cells overexpressing NPNT and that the
localization of NPNT in sEVs is not dependent on the
interaction of NPNT with the integrins.32
Here we examine the sEVs isolated from the supernatant of the
66cl4 cells overexpressing either wild-typeNPNT (66cl4-NPNT)
or NPNT mutated in the integrin binding sites (66cl4-NPNT-
RGE and 66cl4-NPNT-RGEAIA). As a control, 66cl4 cells con-
taining an empty vector (EV) were used (66cl4-EV). We report
several proteins that are differentially packed in sEVs derived from
66cl4-NPNT cells compared to sEVs derived from 66cl4-EV cells.
We have identified NPNT of 80, 60, and 20 kDa when analyzing
whole-cell lysates of 66cl4-NPNT cells. The 80 kDa NPNT is
the highly glycosylated form of the less glycosylated 60 kDa
NPNT. We show here for the first time that a 20 kDa truncated
form of NPNT is highly concentrated in sEVs.
2. MATERIALS AND METHODS
2.1. Cell Culture
The gene for NPNTwas cloned and V5-tagged in the C-terminal,
and the integrin-binding motifs were mutated and expressed in
the mouse breast cancer cell line 66cl4, as previously described.32
Four different variants of 66cl4 cell lines were created that
harbored either an empty vector (66cl4-EV), expressed wild-type
NPNT (66cl4-NPNT), NPNTwhere the RGD integrin-binding
motif was mutated (66cl4-RGE), or where both the RGD and
EIE-integrin binding motifs were mutated (66cl4-RGE-AIA).32
All 66cl4 variants were cultured in (1×) minimum essential
medium α (Thermo Fisher Scientific, Cat. No. 22561021), supple-
mented with 10% fetal calf serum, 1% (v/v) penicillin−strepto-
mycin, and 1 M HEPES buffer (Thermo Fisher Scientific,
Cat. No. 15630080).
2.2. Isolation of Extracellular Vesicles
Fetal calf serum (FCS) was depleted of extracellular vesicles
using serial centrifugation and standard protocols.32,39,40 The
66cl4 cell variants were grown in vesicular-free media for 3 days
to reach approximately 80% confluency. The collected super-
natant was centrifuged at 500g for 10 min to remove cellular
debris. The supernatant was carefully transferred and ultra-
centrifuged at 12 000g for 20 min using a Beckman 70Ti rotor to
isolate microvesicles (MVs) (pellet fraction 1). The supernatant
was transferred to clean tubes and repelleted by ultracentri-
fugation at 100 000g for 70 min, to isolate small extracellular
vesicles (sEVs) (pellet fraction 2). PBS was used to wash both
fractions of MVs and sEVs.
2.3. Preparation for Scanning Electron Microscopy (SEM)
Cultured cells grown on a Thermanox coverslip (Chemi-Teknik
AS, Cat. No. 72280) were fixed with a solution of 2.5% glutar-
aldehyde (GA) (EMgrade distillation purified, Chemi-Teknik AS,
Cat. No. 16310) with 2% paraformaldehyde (PFA) (EMPROVE,
VWR part of Avantor, Cat. No. 104005) in 0.1 MHEPES buffer
for 2−4 h at room temperature. Cells were washed in 0.1 M
HEPES buffer, subsequently dehydrated using increasing
ethanol concentrations (25, 50, 70, 90, 2 × 100%) for 5 min
each, followed by drying using hexamethyldisiloxane (HMDS)
(50% and 2 × 100%, diluted in absolute ethanol) for 20 min
each, and transferred to a desiccator to keep the samples dry.
The dried samples were mounted on aluminum pins with
double-sided carbon tape and sputter coated (Polaron) with
30 nm of gold/palladium. Samples were examined using a scann-
ing electron microscope (Teneo SEM, Thermo Fisher Scientific)
at a voltage of 5 kV.
2.4. Preparation for Transmission ElectronMicroscopy (TEM)
MVs and sEVs isolated and purified as described above were
resuspended and fixed in cold 2% PFA in PBS. Droplets of MVs
and sEVs were put on Formvar-carbon coated copper grids
(200 mesh) for 5 min, fixed in 2.5% GA in 0.1 M Sorensen’s
phosphate buffer for 10 min, washed in reverse osmosis (RO)
water, stained with 2% uranyl acetate (UA) in Milli-Q water for
4 min, and embedded in a solution of 2% UA and 3% poly(vinyl
alcohol) (diluted 1:10) for 10min. The excess liquid on the grids
was then removed with filter paper (hardened) and air-dried.
Grids were examined using a transmission electron microscope
(JSM-1011 TEM, JEOL), at 100.000×magnification and a volt-
age of 80 kV. Images were captured with aMorada digital camera
with iTEM software (BoRAS).
2.5. Uptake of Small Extracellular Vesicles
The pellet of sEVs was labeled with PKH26 (Sigma, MINI26), a
dye taken up by the lipid membrane of sEVs. The 66cl4-EV cells
supplemented with sEVs from 66cl4-EV and 66cl4-NPNT cells
were fixed with 4% PFA for 4 h. Images were captured using
a multichannel fluorescence imaging system (Thermo Fisher
Scientific, EVOS).
2.6. Immunoblotting
Protein lysates were prepared using a mix of RIPA buffer
(Thermo Fischer Scientific, Cat. No. 89901) and HALT phos-
phatase inhibitor single-use cocktail (Thermo Fischer Scientific,
Cat. No. 78428). In some experiments, cells were pretreated
with a final concentration of 100 nM of bafilomycin A1 (Sigma,
Cat. No. SML1661) or 1× eBiocience protein transport inhibitor
cocktail (PTI) (Invitrogen, Cat. No. 00-4980-93) for ≤6 h.
To test the effect of GM6001 (Abcam, Cat. No. ab120845) on
NPNT, cells were exposed to 10 μM of GM6001 for 24 h.
To investigate the post-translational modification of NPNT,
whole cell lysates were digested with different deglycosylation
enzymes as per the manufacturer’s protocol (New England
Biolabs, Cat. Nos. P0704, P0733, and P0720). Samples equivalent
to 30 μg each were loaded on a 10% Bis-Tris gel (Invitrogen).
PVDF membranes were incubated with anti-V5 (CST, 13202)
(1:1000) overnight at 4 °C. Unspecific binding was prevented by
preincubating membrane in 5% BSA for 1 h at room tem-
perature. Anti-GAPDH (Abcam, Cat. No. ab9484) (1:5000)
and Anti-Alix (CST, Cat. No. 2171) were used as markers
for whole cell lysate and sEVs, respectively. Pelleted fractions
were checked for several other vesicular markers as previously
reported.32 HRP linked secondary antibody anti-mouse
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(Dako, Cat. No. P0447) (1:5000) or HRP-linked anti-rabbit
(Dako, Cat. No. P0399) (1:5000) were used. SuperSignal
West femto substrate (Pierce, Cat. No. 34096) with an Odyssey
Fc system (LI-COR Biosciences) was used for image analysis.
2.7. Immunoprecipitation and Gel Electrophoresis
V5-tagged NPNT was pulled down from 7 mg of whole cell
lysates using 100 μL of anti-V5 (CST, Cat. No. 13202) (1:50)
coated Dynabeads protein G (Thermo Fisher Scientific, Cat.
No. 10003D) for 2 h at 4 °C. The beads were washed twice in
PBS and proteins were eluted in LDS sample buffer (Invitrogen)
for gel electrophoresis. 1D-PAGE of eluted proteins was
performed in 10% NuPAGE Noves Bis-Tris gels using MOPS
buffer. Proteins were visualized using SimplyBlue gel stain, and
three bands (20, 60, and 80 kDa) were excised from the gel.
2.8. In Gel Digestion and Mass Spectrometry
SimplyBlue-stained protein bands corresponding to 80, 60, and
20 kDa, respectively, were manually cut out from the gel, and in-
gel tryptic digestion was performed as previously described.41
After desalting,42 peptides were dried down in a SpeedVac
centrifuge and resuspended in 0.1% formic acid. The peptides
were analyzed on a LC−MS/MS platform consisting of an Easy-
nLC 1000 UHPLC system (Thermo Fisher Scientific)
interfaced with an LTQ-Orbitrap Elite hybrid mass spectrom-
eter (Thermo Fisher Scientific) via a nanospray ESI ion source
(Proxeon, Odense). Peptides were injected into a C-18 trap
column (Acclaim PepMap100, 75 μm i.d. × 2 cm, C18, 3 μm,
100 Å, Thermo Fisher Scientific) and further separated on a
C-18 analytical column (Acclaim PepMap100, 75 μm i.d. ×
50 cm, C18, 2 μm, 100 Å, Thermo Fisher Scientific) using a
multistep gradient with buffer A (0.1% formic acid) and buffer
B (CH3CN, 0.1% formic acid): From 0 to 6% B in 5min, 6−12%
B in 39 min, 12−20% B in 80 min, 20−28% B in 31 min,
28−40% B in 4 min, 40−100% B in 1 min, 100% B in 9 min,
100−0% B in 1 min, and 10 min with 100% A. The flow rate was
250 nL/min. Peptides eluted were analyzed on the LTQ-
Orbitrap Elite hybrid mass spectrometer operating in positive
ion and data-dependent acquisition mode using the following
parameters: electrospray voltage 1.9 kV, CID fragmentation
with normalized collision energy 35, and automatic gain control
target value of 1E6 for Orbitrap MS and 1E3 for MS/MS scans.
Each MS scan (m/z 300−1600) was acquired at a resolution of
120 000 fwhm, followed by 20 MS/MS scans triggered for
intensities above 500, at a maximum ion injection time of 200ms
for MS and 120 ms for MS/MS scans.
Proteins were quantified by processing MS data using Max
Quant v 1.5.8.3.43 Preview 2.3.5 (Protein Metrics Inc.) was used
to inspect the raw data to determine optimal search criteria.
The following search parameters were used: enzyme specified as
trypsin with a maximum of two missed cleavages allowed;
mass tolerance set to 20 ppm; oxidation of methionine and
deamidation of asparagine and glutamine as dynamic post-
translational modification, and carbamidomethylation of cys-
teine as a fixedmodification. These were imported inMaxQuant,
which uses m/z and RT values to align each run against each
other sample with 1 min window match-between-run function
and 20 min overall sliding window using a clustering-based
technique. These are further queried against the UniProtKB/
Swiss-Prot database (Release April 2017 Mouse proteome with
isoforms; 59684 sequences and MaxQuant’s internal contam-
inants database) using Andromeda built into MaxQuant.
Both protein and peptide identifications FDR were set to 1%;
thus, only peptides with high confidence were used for final
protein group identification. Peak abundances were extracted
by integrating the area under the peak curve. Each protein
group abundance was normalized by the total abundance of all
identified peptides for each run and protein by calculated
median summing all unique and razor peptide ion abundances
for each protein using a label-free quantification algorithm44
with minimum peptides ≥1. Protein group abundances were
imported and analyzed using R software. Given the structure of
the data, the statistical analysis was performed using a two-way
analysis of variance (ANOVA) in order to consider the levels
of variance at batch as well as test groups. Data were log
2-transformed before the analysis. Proteins were considered
identified if they were quantified in at least 75% of the biological
replicates. Noise with a standard deviation of 0.01 was added to
compensate for the missing values followed by principal
component analysis to find and remove the batch effect.
Table S1 of the Supporting Information (SI) contains
normalized log 2 intensity counts and corresponding values
after the removal of the component. Perseus plugins45 are used
to carry out these steps. The latter values are only presented for
those which have permutation based FDR < 5%with S0 of 0.1.46
These are computed over Z-scored values with their medians,
namely, the row representing the proteins intensities and the
column representing the samples are shifted by the median of
Figure 1. Overexpression of NPNT in 66cl4 cells does not affect the
secretion or uptake of sEVs. (a) SEM of 66cl4-EV and 66cl4-NPNT
cells cultured in medium free of serum vesicles for 24 h showed
extracellular vesicles released by these cells. Red arrows point at
potential extracellular vesicles. Scale bar, upper row 5 μm and lower row
2 μm. (b) Fractions of MVs and sEVs isolated from 66cl4-EV and
66cl4-NPNT cell lines were stained with uranyl acetate and viewed by
electron microscopy. Scale bar, 100 nm. (c) 66cl4-EV cells were
incubated with 40 μg of PKH26-stained sEVs derived from 66cl4-EV
and 66cl4-NPNT cells and imaged after 4 h to check for internalization
of exosomes. Scale bar, 100 μm.
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the row and scaled by the standard deviation. Pearson’s corre-
lation coefficients were calculated in both dimensions over these
values, which were further used for hierarchical clustering using
an average linkage procedure (Figure 2d).
2.9. Ingenuity Pathway Analysis
In order to characterize the enrichment of functional category
for selected protein groups (Table S1, SI, list of protein
groups with permutation based FDR < 5% and S0 of 0.1), the
Figure 2. Overexpression of NPNT in 66cl4 cells alters the content of sEVs. (a) Venn diagram of proteins identified in sEVs isolated from 66cl4-EV
and 66cl4-NPNT cells. A total 1754 proteins were identified to be common between the sEVs isolated from both of the cell lines. The numbers indicate
that a certain protein was present in at least three out of four replicates. (b) Pie chart showing the distribution of 1754 common proteins based on their
subcellular localization. (c) Pie chart showing the distribution of 1754 common proteins based on their molecular nature. (d) Heat map of proteins
differentially expressed in sEVs derived from 66cl4-EV and 66cl4-NPNT cells, considering proteins from all four replicates. (e) Top canonical
pathways and cellular functions predicted by IPA analyses using a list of proteins differentially expressed in sEVs derived from 66cl4-EV and 66cl4-
NPNT cells.
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two broad clusters were mapped to the canonical pathways
database of Ingenuity Pathway Analysis (IPA) (Qiagen).47
The p-values based on Fisher’s exact test over categorical
distribution are corrected using Benjamini Hochberg procedure.
They represent the statistical significance of the identified
canonical functions, namely, the lower the p-value, the higher
the proportion of identified proteins, overlapping with the
particular canonical function.
Figure 3. Truncated form of NPNT is concentrated in sEVs isolated from 66cl4-NPNT cells. (a) Immunoblotting for V5-tagged
NPNT using whole cell lysates of 66cl4-EV, 66cl4-NPNT, 66cl4-NPNT-RGE, and 66cl4-NPNT-RGEAIA cells. (b) Immunoblotting for
V5-tagged NPNT using lysates made from the sEVs isolated from supernatant of 66cl4-EV, 66cl4-NPNT, 66cl4-NPNT-RGE, and 66cl4-NPNT-
RGEAIA cells. (c) Positional information on mouse NPNT sequences used for characterization of NPNT. Lysates made from whole cell
(d) and small extracellular vesicles (e) of 66cl4 cells overexpressing NPNT were treated with different glycosylation enzymes and observed for
reduction in the molecular size of NPNT. “-N” denotes removal of N-glycosylation by PNGase F treatment. “-O” denotes removal of
O-glycosylation by O-glycosidase. “-S” symbolizes removal of the sialic acid cap. “-O&S” denotes removal of the sialic acid cap
and O-glycosylation.
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3. RESULTS AND DISCUSSION
3.1. Overexpression of NPNT in 66cl4 Cells Does Not Affect
the Secretion or Uptake of sEVs
To visualize the surface morphology and sEVs of 66cl4 cells, we
utilized SEM. Several spherical particles in the nanometer range
were observed on/around the cell surface (Figure 1a), suggest-
ing the presence of extracellular vesicles. To confirm the pre-
sence of extracellular vesicles, we used differential ultracentri-
fugation and isolated extracellular vesicles from the supernatant
of the 66cl4 cells, where pellet fraction 1 was collected upon
spinning at 12 000g for 20min and pellet fraction 2 was collected
upon spinning at 100 000 g for 70 min. The isolated extracellular
vesicles in the two pellets were characterized byTEM(Figure 1b),
which is considered to be a standard tool for characterizing extra-
cellular vesicles.48 Double membrane vesicles were identified in
both pelleted fractions 1 and 2. Fraction 1 displayed a homogen-
eous population of vesicles within the range 100−1000 nm, char-
acteristic of MVs. Fraction 2 displayed vesicles within the range of
30−100 nm in diameter, characteristic of sEVs (Figure 1b). Overe-
xpression of NPNT in 66cl4 cells did not alter the morphology nor
the size of the MVs and sEVs, as observed by TEM analyses. The
ability of sEVs to exert a functional effect mainly depends on their
internalization and subsequent release of its content in recipient
cells. We have previously detected NPNT protein in sEVs derived
from 66cl4-NPNT cells.32 To investigate if the presence or absence
of NPNT in the sEVs affects its uptake, we treated sEVs derived
from 66cl4-EV and 66cl4-NPNT cells with PKH26, a lypophilic
dye, for 4 h prior to fixing and thorough washing of cells with PBS.
PKH26-labeled vesicles were observed as red dots on and most
likely within 66cl4-EV cells (Figure 1c), indicating that these
vesicles are taken up or are bound to the surface of 66cl4-EV cells
irrespective of their source and content.
3.2. Overexpression of NPNT in 66cl4 Cells Alters the
Content of sEVs
To investigate the protein composition of sEVs upon NPNT
overexpression, shotgun MS was performed on lysed sEVs
derived from 66cl4-EV and 66cl4-NPNT cells. The Venn
diagram (Figure 2a) shows the number of proteins identified in
sEVs isolated from 66cl4-EV and 66cl4-NPNT cells. A total of
1754 proteins were identified to be common between the sEVs
isolated from both cell lines. As expected, several well-known
tumor and vesicular markers were detected in this common
fraction between sEVs of both cell lines (Figure S1a, SI). A 62%
similarity to the previously reported sEVs derived from parental
66cl4 cells was observed.33 IPA analyses suggest that the majority
of proteins in our data came from the cytoplasmic fraction of the
cell (Figure 2b) andwere enzymatic in nature (Figure 2c). NPNT
was detected as one of the 276 proteins found only in sEVs
derived from 66cl4-NPNT cells [Figure 2a and Table S1 (SI)].
Several kinases known for their role in tumor development,
such as mTOR49 and JAK,50 were detected only in sEVs from
66cl4-NPNT cells (Table S1, SI). Ceruloplasmin, a known
biomarker for breast cancer,51 was only present in sEVs from
66cl4-NPNT cells. Two major clusters were identified when
protein IDs passing a false discovery rate of 5% were clustered
over Z-scores [Figure 2d and Table S1 (SI)]. NPNT is known to
bind to different types of integrins,52 and IPA analyses showed
that several proteins identified in sEVs derived from 66cl4-NPNT
cells are involved in integrin signaling pathways and are predicted
to increase proliferation, cell survival, and organization of
cytoskeleton/cytoplasm (Figure 2e). Several other studies have
shown that a change in a single oncoprotein/oncogene can alter
the contents of vesicular cargo and further incorporate tumor-
promoting proteins in sEVs.31,53−55 Taken together, the
proteins enriched in sEVs derived from NPNT-expressing
breast cancer cells might represent markers that are involved in
mechanisms affecting breast cancer progression and metastasis.
3.3. Truncated Form of NPNT Is Concentrated in sEVs
Isolated from 66cl4-NPNT Cells
The predicted molecular weight of mouse NPNT (561 amino
acids) is 61 kDa. Our immunoblot analysis of 66cl4 cells overe-
xpressing full length NPNT with a C-terminal V5-tag showed
three bands of approximately 20, 60, and 80 kDa (Figure 3a).
Interestingly, immunoblotting of lysed sEVs revealed only two
bands, one at 20 and 80 kDa (Figure 3b). At the same time there
was an increase in the relative amount of the 20 kDa NPNT in
sEVs compared to the 80 kDa NPNT (Figure 3b). This could
indicate that there is a selective sorting process involved in the
vesicular packaging of NPNT. This phenomenon of the 20 kDa
NPNT being concentrated was seen in both sEVs (Figure 3b)
and MVs (Figure S1b, SI). Of note, we have observed that the
quality of immunoblot is compromised upon freeze−thaw cycles
of sEVs, and this might explain the difference in intensities in the
20 kDa bands in parts b and e of Figure 3.
To investigate whether the different apparent sizes of NPNT
were due to post-translational modifications, we pulled-down
NPNT from the whole cell lysates using V5 antibody and
analyzed it by MS. Six unique NPNT peptide sequences were
detected in the 80 kDa NPNT (Table 1), covering almost the
full span of the protein (Figure 3c). This verifies that the 80 kDa
NPNT is a full-length version of the protein. Four unique
peptides matched the 60 kDa NPNT, including the first peptide
(amino acids 28−37), indicating that the 60 kDa NPNT is most
likely also a full-length version of the protein. One unique
NPNT-derived peptide was detected in the 20 kDa NPNT
(amino acid 446−459). This indicates that the 20 kDa NPNT is
mostly harboring theMAMdomain of the C-terminal part of the
protein. Further, to identify whether post-translational mod-
ifications such as glycosylation contribute to differences between
the three NPNT bands, whole cell lysates and sEVs were treated
with PNGase F, O-glycosidase, or α2-3,6,8 neuraminidase.
These enzymes remove N- andO-linked glycans with or without
a sialic acid cap, thereby reducing the apparent molecular size of
NPNT on immunoblots. Upon PNGase F treatment (-N), a
reduction in the molecular size was observed for both the
60 and 80 kDa bands in whole cell lysates (Figure 3d) and for
the 80 kDaNPNT of sEVs (Figure 3e). There was no shift in any













QIVSSIGLCR 10 28 37 − √ √
CQCPSPGLQLAPDGR 15 151 165 − − √
TCVDIDECATGR 12 166 177 − √ √
EKDSDLHWETAR 12 405 416 − √ √
DSDLHWETAR 10 407 416 − √ √
DPAGGQYLTVSAAK 14 417 430 √ − √
aWhole cell lysates from 66cl4-NPNT cells were separated on the
basis of their size by gel electrophoresis after immunoprecipitation
with anti-V5-coated beads. In the eluted proteins, different NPNT
tryptic peptides were detected in the 80, 60 and 20 kDa NPNT-V5
bands. The table represents results from three biological replicates.
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of the bands upon treatment with O-glycosidase (-O) alone.
However, cotreatment with O-glycosidase and α2-3,6,8
neuraminidase (-S) resulted in a major band shift in the
80 kDa NPNT for both cell and sEVs lysates. This suggests that
the 80 kDa NPNT has O-glycosylation but with a sialic acid cap.
A similar glycosylation pattern of NPNT secreted by osteo-
blasts has previously been reported.56 A high degree of N- and
O-glycosylation is predicted in the region between the EGF
repeats and the MAM domains.52 Aberrant glycosylation
patterns of secreted glycoproteins are known to contribute in
tumor development and progression.57,58 It remains to be
investigated whether the glycosylation pattern of NPNT would
influence breast cancer progression. The glycosylation patterns
are also crucial for sorting of proteins into extracellular vesi-
cles.59−61 Our results indicate that the 60 kDa band is far less
glycosylated than the 80 kDa band, while the 20 kDa band is not
glycosylated. The heavily glycosylated 80 kDa NPNT, contain-
ing bothN- andO-glycosylations is recruited into sEVs (Figure 3e),
while the less glycosylated 60 kDa NPNT is not detected in
either sEVs or MVs. N-Glycosylations are mainly added when
proteins transition through the endoplasmic reticulum,62 while
O-glycosylations are generally initiated in Golgi.63
Figure 4. Intracellular protein trafficking controls the protein level of the truncated form of NPNT. (a) Immunoblotting for V5-taggedNPNTwas used
to detect differential expression of NPNTwhen 66cl4-overexpressing cells were exposed to 100 nMBafA1 or 1× PTI. (b) Immunoblotting was used to
detect differential expression of V5-tagged NPNT in 66cl4-RGE cells after exposure to 100 nM BafA1 or 1X PTI for 6 h. (c) Immunoblotting for V5-
taggedNPNT using whole cell lysates of 66cl4-RGE-AIA cells after exposure to 100 nMBafA1 or 1× PTI for 6 h. Results here are presented in terms of
a fold change after normalizing with GAPDH. Quantification of optical density represents the mean of at least three independent experiments.
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3.4. Intracellular Protein Trafficking Controls the Protein
Levels of the Truncated NPNT
The intracellular protein trafficking pathways are often
manipulated in cancer cells, and a better understanding of this
aspect is important for developing therapeutic interventions.64
To investigate the intracellular NPNT trafficking, we employed
a mixture of brefeldin A and monensin, to block transport from
the endoplasmic reticulum to the Golgi apparatus, and bafilomy-
cin A1 (BafA1), which inhibits degradation of endocytosed
“cargo” by neutralizing the lysosomes65 (Figure 5c). Hence, any
Figure 5. Matrix metalloproteinases are involved in proteolytic processing of full-length NPNT. (a) Immunoblotting for V5-tagged NPNT after
exposure to 10 μMGM6001 for 24 h. Results here are presented in terms of a fold change after normalizing with GAPDH. Quantification of the optical
density represents the mean of at least three independent experiments. (b) Illustration showing the structural differences in NPNT at 80, 60, and 20
kDa. The 80 kDaNPNT is the full-length protein having a putative signal peptide, the EGF repeats, glycosylation sites, integrin binding motifs, and the
MAMdomain. The 60 kDaNPNT is also a full-length protein but with fewer attached glycans, as opposed to the 80 kDaNPNT. The 20 kDaNPNT is
the truncated form of NPNT harboring mainly the MAM domain and the C-terminal V5-tag. (c) Illustration showing the probable route of NPNT
secretion, endocytosis, degradation, or selective sorting into extracellular vesicles. Upon glycosylation at the endoplasmic reticulum and Golgi, NPNT
is secreted via secretory vesicles. The secreted NPNT probably interacts with cell surface receptors such as integrins or is cleaved by matrix
metalloproteases (MMPs). The cleaved NPNT adhering to the cell surface could further be taken up and be released as exosomes or degraded by
lysosomes, depending on the fate of multivesiclular bodies.
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endocytosed protein, including NPNT, ends up being
accumulated in the cytoplasm. 66cl4-EV and -NPNT cells
were exposed to 100 nM BafA1, and whole cell lysates were
harvested and analyzed by immunoblotting for the V5-tag.
By inhibiting degradation of endocytosed proteins, there was a
significant accumulation of the 20 kDa NPNT (Figure 4a) and a
slight increase in 80 kDa NPNT. 66cl4-EV and -NPNT cells
were exposed to 1× protein transport inhibitor cocktail (1×
PTI), and whole cell lysates were harvested and analyzed by
immunoblotting for the V5-tag. Inhibiting the secretion resulted
in an accumulation of the 60 kDa band of NPNT, with a corre-
sponding reduction of the 80 and 20 kDa bands (Figure 4a).
Cells expressing the mutated forms of NPNT showed similar
changes when exposed to PTI or BafA1 (Figure 4b,c). Taken
together, these results indicate that the 60 kDa NPNT is not a
secreted version of NPNT, but rather the “native” protein. This
could also explain the limited amount of glycosylations present
in the 60 kDa NPNT (Figure 3a) and its absence in the sEVs
(Figure 3b). Both 80 and 20 kDa accumulate in the cytoplasm
upon BafA1 treatment, indicating that they are both endo-
cytosed from the extracellular milieu. The 80 kDaNPNT is most
likely the secreted full-length version of NPNT, having both
N- and sialic acid capped O-glycosylations.
3.5. Matrix Metalloproteinases (MMPs) Are Involved in
Proteolytic Processing of Full-Length NPNT
Having identified the truncated form of NPNT, we further
analyzed whether proteases such as MMPs are involved in this
processing by utilizing GM6001, a broad-spectrumMMP inhib-
itor. 66cl4-NPNT cells were treated with 10 μM GM6001 for
24 h and whole cell lysates were analyzed by immunoblotting for
the V5-tag. A significant reduction in the relative amounts of
20 kDa NPNT was observed (Figure 5a). We already know that
the extracellularly located 80 kDa NPNT can be endocytosed by
the cells. When MMP cleavage is inhibited, the amount of
endocytosed 20 kDa NPNT is reduced. This indicates that the
20 kDa NPNT is a cleaved form of NPNT and that this cleavage
is at least in part mediated by MMPs. MMPs can cleave pro-
teins intracellularly and extracellularly.66 Several metalloprotei-
nases are also packed inside extracellular vesicles, capable
of further altering the vesicular cargo by proteolytic process-
ing.67,68 Cleaved proteins packed in tumor-derived extracellular
vesicles are reported to be biologically active.55,69 Further
investigation is needed to identify if the cleaved NPNT packed
in sEVs has a biological significance. Our study on NPNT
trafficking in 66cl4 cells is the first to report a truncated form of
NPNT at 20 kDa, mainly harboring the MAM domain part of
the protein (Figure 5b). The exact MMP cleavage site and the
identity of the MMPs capable of cleaving NPNT remain to be
determined.
Though there are several challenges while analyzing the vesi-
cular proteome usingMS, the composition of sEVs derived from
66cl4-NPNT cells helps us to picture the molecular fingerprint
of exosomes in cells with high NPNT levels. Results from the
current study are summarized in Figure 5c and show that the
native form of NPNT gets glycosylated and modified at the
endoplasmic reticulum and Golgi and that the secreted full-
length NPNT (80 kDa) probably gets cleaved by MMPs.
Both the highly glycosylated NPNT (80 kDa) and the truncated
form of NPNT (20 kDa) are perhaps endocytosed/pinocytosed
and get incorporated into the ILVs within a MVB. These ILVs
packed with NPNT inside a MVB can either be released as
exosomes or be degraded by lysosomes.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the ACS
Publications website at DOI: 10.1021/acs.jproteome.8b00859.
Table S1 in spreadsheet format (XLSX)
Figure S1, a list of well-known tumor and vesicular
markers detected in sEVs isolated from 66cl4-EV and
66cl4-NPNT cells and mmunoblotting for V5-tagged
NPNT using lysates made from the microvesicles isolated
from the supernatant of 66cl4-EV and 66cl4-NPNT cells,
and Table S1, a list of proteins identified in sEVs isolated
from 66cl4-EV and 66cl4-NPNT cells (PDF)
■ AUTHOR INFORMATION
Corresponding Author






The authors declare no competing financial interest.
The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner
repository with the dataset identifier PXD010999.70,71
■ ACKNOWLEDGMENTS
The study received funding from the Central Norway Regional
Health Authority (Project number: 46077600), North Norwe-
gian Regional Health Authorities (Project number SFP1232-
15), The Erna and Olav Aakre Foundation for Cancer Research,
The Blix Family Fund for Medical Research, CMIC, and UiT.
Dr. Fred Miller kindly provided 66cl4 and 4T1 mouse cell lines.
Data storage and handling is supported under the Norstore/
Notur project NN9036K and PRIDE. We express our gratitude
to Dr. Naoko Morimura for the pcDNA3-POEM-Fc vector and
Dr. Peter McCourt for linguistic revision. We thank Hector
Peinado, Lucia Robado de Lope, and Marta Hergueta-Redondo
for collaboration regarding exosome isolation protocols.
■ REFERENCES
(1) The International Society for Extracellular Vesicles. www.isev.org.
(2) van der Pol, E.; Boing, A. N.; Harrison, P.; Sturk, A.; Nieuwland, R.
Classification, functions, and clinical relevance of extracellular vesicles.
Pharmacol. Rev. 2012, 64 (3), 676−705.
(3) Pucci, F.; Pittet, M. J. Molecular pathways: tumor-derived
microvesicles and their interactions with immune cells in vivo. Clin.
Cancer Res. 2013, 19 (10), 2598−604.
(4) Jansen, F.; Yang, X.; Proebsting, S.; Hoelscher, M.; Przybilla, D.;
Baumann, K.; Schmitz, T.; Dolf, A.; Endl, E.; Franklin, B. S.; Sinning, J.
M.; Vasa-Nicotera, M.; Nickenig, G.;Werner, N.MicroRNA expression
in circulating microvesicles predicts cardiovascular events in patients
with coronary artery disease. J. Am. Heart Assoc. 2014, 3 (6), e001249.
(5) Palmulli, R.; van Niel, G. To be or not to be··· secreted as
exosomes, a balance finely tuned by the mechanisms of biogenesis.
Essays Biochem. 2018, 62 (2), 177−191.
(6) Thery, C. Exosomes: secreted vesicles and intercellular
communications. F1000 Biol. Rep. 2011, 3, 15.
(7) Pan, B. T.; Teng, K.; Wu, C.; Adam,M.; Johnstone, R. M. Electron
microscopic evidence for externalization of the transferrin receptor in
vesicular form in sheep reticulocytes. J. Cell Biol. 1985, 101 (3), 942−8.
Journal of Proteome Research Article
DOI: 10.1021/acs.jproteome.8b00859
J. Proteome Res. 2019, 18, 1237−1247
1245
(8) Harding, C.; Heuser, J.; Stahl, P. Endocytosis and intracellular
processing of transferrin and colloidal gold-transferrin in rat
reticulocytes: demonstration of a pathway for receptor shedding. Eur.
J. Cell Biol. 1984, 35 (2), 256−63.
(9) Montecalvo, A.; Larregina, A. T.; Shufesky, W. J.; Stolz, D. B.;
Sullivan, M. L.; Karlsson, J. M.; Baty, C. J.; Gibson, G. A.; Erdos, G.;
Wang, Z.; Milosevic, J.; Tkacheva, O. A.; Divito, S. J.; Jordan, R.; Lyons-
Weiler, J.; Watkins, S. C.; Morelli, A. E. Mechanism of transfer of
functional microRNAs between mouse dendritic cells via exosomes.
Blood 2012, 119 (3), 756−66.
(10) Costa Verdera, H.; Gitz-Francois, J. J.; Schiffelers, R. M.; Vader,
P. Cellular uptake of extracellular vesicles is mediated by clathrin-
independent endocytosis and macropinocytosis. J. Controlled Release
2017, 266, 100−108.
(11) Li, P.; Kaslan,M.; Lee, S. H.; Yao, J.; Gao, Z. Progress in Exosome
Isolation Techniques. Theranostics 2017, 7 (3), 789−804.
(12) Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and
characterization of exosomes from cell culture supernatants and
biological fluids. Current Protocols in Cell Biology; Wiley, 2006; Chapter
3, Unit 3.22.
(13) Bobrie, A.; Colombo, M.; Krumeich, S.; Raposo, G.; Thery, C.
Diverse subpopulations of vesicles secreted by different intracellular
mechanisms are present in exosome preparations obtained by
differential ultracentrifugation. J. Extracell. Vesicles 2012, 1, 18397.
(14) Willms, E.; Johansson, H. J.; Mager, I.; Lee, Y.; Blomberg, K. E.;
Sadik, M.; Alaarg, A.; Smith, C. I.; Lehtio, J.; El Andaloussi, S.; Wood,
M. J.; Vader, P. Cells release subpopulations of exosomes with distinct
molecular and biological properties. Sci. Rep. 2016, 6, 22519.
(15) Kowal, J.; Arras, G.; Colombo, M.; Jouve, M.; Morath, J. P.;
Primdal-Bengtson, B.; Dingli, F.; Loew, D.; Tkach, M.; Thery, C.
Proteomic comparison defines novel markers to characterize
heterogeneous populations of extracellular vesicle subtypes. Proc.
Natl. Acad. Sci. U. S. A. 2016, 113 (8), E968−77.
(16) Zhang, H.; Freitas, D.; Kim, H. S.; Fabijanic, K.; Li, Z.; Chen, H.;
Mark, M. T.; Molina, H.; Martin, A. B.; Bojmar, L.; Fang, J.;
Rampersaud, S.; Hoshino, A.; Matei, I.; Kenific, C. M.; Nakajima, M.;
Mutvei, A. P.; Sansone, P.; Buehring, W.; Wang, H.; Jimenez, J. P.;
Cohen-Gould, L.; Paknejad, N.; Brendel, M.; Manova-Todorova, K.;
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